胶质母细胞瘤随机III期试验MIRAGE的放疗质控:勾画基准病例流程结果
MIRAGE试验在入组前要求所有参与中心提交勾画与计划基准病例,由放疗质控团队前瞻性审核并要求不合规中心修改重交。88家机构的勾画中80%被判定为不可接受变异,靶区比危及器官更常不合格;审核后靶区和部分危及器官的Dice相似系数显著提高,CTV D98%平均增加2.2 Gy(4%,p=0.005)。
要点
- 88家机构中80%(n=70)的基准病例勾画被判定含不可接受变异。
- 靶区勾画不可接受率高于危及器官(72% vs 55%)。
- 审核后靶区与部分危及器官DSC显著提高,CTV D98%平均增加2.2 Gy。
核心结论
- 基准病例放疗质控审核中,靶区和危及器官勾画变异常被判定为不可接受。
- 审核后勾画一致性显著改善,CTV覆盖显著提高,危及器官剂量无显著变化但仍满足预设约束。
- 建议探索量化指标评估勾画变异,以改进临床试验和常规实践中的放疗质控流程。
研究设计与样本
- 多中心随机III期试验EORTC-1709-BTG/CCTG CE.8(MIRAGE)(NCT03345095)的放疗质控分析。
- 试验分析在替莫唑胺为基础放化疗(60 Gy/30次)基础上加用蛋白酶体抑制剂marizomib治疗新诊断胶质母细胞瘤。
- 试验启动前要求所有参与中心提交同一基准病例的放疗靶区勾画和计划,质控团队前瞻性审核,不可接受者需修改重交直至符合方案。
- 分析88家机构提交的同一基准患者结构集和剂量分布,比较首次与最终提交的勾画变异。
主要发现
- 88家机构勾画中80%(n=70)被放疗质控审核者判定为不可接受变异。
- 靶区勾画不可接受率72%,危及器官55%。
- 审核后平均DSC显著提高:GTV 0.77 vs 0.82(p=0.002),CTV 0.85 vs 0.88(p<0.0001),PTV 0.85 vs 0.88(p<0.0001)。
- 审核后脑干DSC 0.87 vs 0.88(p=0.007),耳蜗0.58 vs 0.62(p=0.004),视神经0.65 vs 0.67(p=0.0005)。
- 审核后勾画调整使平均CTV D98%显著增加2.2 Gy(4%,p=0.005),危及器官剂量无显著变化但仍满足预设约束。
关键数值与推荐
- 放疗剂量为60 Gy分30次,与替莫唑胺为基础放化疗联合。
- 靶区勾画不可接受率72%,危及器官不可接受率55%,总体80%(n=70/88)。
- CTV D98%平均增加2.2 Gy(4%,p=0.005)。
临床怎么用
- 多中心胶质母细胞瘤放疗试验或临床实践中,入组前应执行基准病例勾画与计划质控审核。
- 对不可接受变异要求修改重交直至方案合规,可显著改善靶区勾画一致性和CTV覆盖。
- 可探索量化勾画变异指标,以标记对肿瘤控制或毒性有影响的变异。
局限性
- 分析基于同一基准病例,非各中心实际治疗患者。
- 危及器官剂量变化不显著,对毒性结局的影响仅为推测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The multicentre randomised phase III trial EORTC-1709-BTG/CCTG CE.8 (MIRAGE) (NCT03345095) analysed the addition of the proteasome inhibitor marizomib to temozolomide-based chemoradiotherapy with 60 Gy in 30 fractions in patients with newly diagnosed glioblastoma. Here, we analysed the benchmark case procedure for delineation and planning radiotherapy quality assurance (RTQA) that was performed before patient inclusion. MATERIALS AND METHODS: Prior to trial activation, all participating centers were required to submit a benchmark case for radiotherapy volume delineation and planning. Submissions were prospectively reviewed by the RTQA team, and in cases of unacceptable variations, centers were required to revise and resubmit the same case until protocol compliance was achieved. Structure sets and dose distributions of the same benchmark patient submitted by participating centres were analysed. We determined the rate and causes of variations of glioblastoma target volumes (TV) and organs at risk (OAR) from the protocol-specified delineation guidelines. Delineation interobserver variability before and after RTQA review were quantified using the Dice similarity coefficient (DSC) with respect to ground truth contours at first and final submission of the benchmark case. The influence of reducing delineation interobserver variability on dose parameters of ground truth structures was determined. RESULTS: The delineations by 88 institutes were judged by RTQA reviewers to contain "unacceptable" variations in 80 % (n = 70) of the cases. TV contours were more frequently deemed unacceptable than organs at risk (72 % vs 55 %). After RTQA review, the mean DSC significantly improved for TV (GTV: 0.77 vs 0.82, p = 0.002; CTV: 0.85 vs 0.88, p < 0.0001; PTV: 0.85 vs 0.88, p < 0.0001), brainstem (0.87 vs 0.88, p = 0.007), cochlea (0.58 vs 0.62, p = 0.004) and optic nerve (0.65 vs 0.67, p = 0.0005), indicating reduced interobserver variability. The delineation adjustments after RTQA review resulted in a significant increase of the mean CTV D98% (+2.2 Gy, +4%, p = 0.005), indicating an improved target coverage. Doses to organs at risk did not change significantly but still met predefined constraints. CONCLUSIONS: Variations in the delineation of target volumes and organs at risk were frequently judged as "unacceptable" during the RTQA review process. Besides a significant increase of CTV coverage, the impact of variations on organ at risk dosimetry was minor, suggesting a potentially negligible effect on toxicity outcomes. Quantitative metrics to assess delineation variations should be explored to improve the RTQA process in clinical trials and routine practice, aiming to flag delineation variations that confer an effect on tumour control or toxicity.
引用
- Willmann J, Verhoeff JJC, Kaidar-Person O, et al. Quality assurance in the randomized multicentre phase III trial EORTC-1709-BTG/CCTG CE.8 (MIRAGE) for glioblastoma: Results of the radiotherapy delineation benchmark case procedure. Radiother Oncol. 2025. PMID: 40796015. doi:10.1016/j.radonc.2025.111088
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。